Ke Xu is a distinguished researcher with over a decade of experience in basic biomedical research. His focus lies in exploring the regulatory relationship between the immune system and metabolism, revealing the crucial role of nutrient metabolism in immune response regulation. Ke Xu's work has led to novel therapeutic strategies for self-immune diseases and cancer. His significant scientific contributions have been published in renowned journals such as Science and Immunity. Additionally, he has served as a consultant for PreScouter Inc. and provided valuable insights to leading biotechnology companies. With 9 SCI papers and over 1100 citations, Ke Xu's research has made a substantial impact in the field.

Anjin XianYu is an experienced neurobiologist and data scientist with 3 SCI publications to date. He has been accepted to Insight Data Science's Health Data Science program. He was a Senior Data Scientist and Director of Data Science at PatientsLikeMe before returning to China to start his own business.

Graduate from the Weill Cornell Medicine-Memorial Sloan Kettering Cancer Center joint doctoral program, Dr.Cao is an inquisitive scientist. Dr. Cao studied under his doctoral advisor Dr. Charles Sawyers, the pioneer of targeted cancer therapies, also the inventor of Gleevec - the most effective CML treatment up-to-date. Dr. Sawyers is also a member of the U.S. National Academy of Sciences and the U.S. College of Medicine, and the recipient of the Lasker Prize - the highest award in the medical sciences, as well as the Breakthrough Prize in the Life Sciences. During his 10+ years of biomedical research and the training under Dr.Sawyers, Dr. Cao has co-authored a total of 17 high-profile academic papers with more than 3,500 citations. His research ranged from cellular molecular biology to tumor pathiology. Dr. Cao also specializes in analyzing genetic databases of cancer patients through data mining and using organoids and animal models to validate potential therapeutic targets. At META, he is responsible for the establishment and research at our Hong Kong laboratory, where META is exploring extra potential combination therapy areas (e.g., oncology, etc.) for our core pipeline and providing efficient experimental validation of translational medicine for our multi-omics target discovery platform.

Mr. Tang holds a Master's degree in Economic Sociology from the University of Cambridge and a Bachelor's degree in Economics from Durham University, with extensive experience in investment banking and biopharmaceutical financing. Prior to joining META Pharmaceuticals, Mr. Tang served at China Development Bank and Orient Securities Group, where he held the position of Associate Vice President in the Investment Banking Department of Orient Investment Bank (formerly Citi Orient Securities). During his tenure, he led and played a key role in numerous M&A and financing projects for biopharmaceutical companies, covering innovative drug therapies, in vitro diagnostics, and investments in pharmaceutical and medical device listed companies. With profound expertise in corporate governance and capital operations, Mr. Tang's experience spans financial control, business operations, legal compliance, and financing expansion. At META Pharmaceuticals, he oversees strategic investment and financing planning, operational management, and key business collaborations.